A Phase II Study of Imetelstat (GRN163L, NSC# 754228) in Children With Relapsed or Refractory Solid Tumors.

Trial Profile

A Phase II Study of Imetelstat (GRN163L, NSC# 754228) in Children With Relapsed or Refractory Solid Tumors.

Suspended
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2017

At a glance

  • Drugs Imetelstat (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Mar 2014 According to the ClinicalTrials.gov record, status changed from not yet recruiting to suspended.
    • 30 Jan 2014 According to the ClinicalTrials.gov record, planned initiation date changed from 1 Dec 2013 to 1 Jan 2014.
    • 18 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top